Related Experiment Video
Updated: Mar 11, 2026

FISH for Pre-implantation Genetic Diagnosis
Published on: February 23, 2011
Attitudes of European Geneticists Regarding Expanded Carrier Screening
Objective:
To explore attitudes of clinical and molecular geneticists about the implementation of multi-disease or expanded carrier screening (ECS) for monogenic recessive disorders.
Design:
Qualitative; semistructured interviews.
Setting:
In person or via Skype. Interviews were audiorecorded and transcribed verbatim.
Participants:
European clinical and molecular geneticists with expertise in carrier screening (N = 16).
Methods:
Inductive content analysis was used to identify common content categories in the data.
Results:
Participants recognized important benefits of ECS, but they also identified major challenges, including limited benefit of ECS for most couples in the general population, lack of knowledge on carrier screening among nongenetic health care providers and the general public, potential negative implications of ECS for society, and limited economic resources. Participants favored an evidence-based approach to the implementation of population-wide ECS and were reluctant to actively offer ECS in the absence of demonstrable benefits. However, there was a consensus among the participants that ECS should be made available to couples who request the test. In addition, they believed ECS could be routinely offered to all people who use assisted reproduction.
Conclusion:
Although a limited ECS offer is practical, it also raises concerns over equality in access to screening. A comprehensive risk-benefit analysis is needed to determine the desirability of systematic population-wide ECS.
More Related Videos
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Incomplete Dominance
Pharmacogenomics: Identification of New Drug Targets
What is Genetic Engineering?
CRISPR

